Nanopharmaceuticals are colloidal particles of 10 to 1,000 nanometers (1 micron) in size. They are widely used in drug delivery. Nanopharmaceuticals are diverse both in their shape and composition and often offer an advantage as compared to their bulk counterparts primarily because of size.
There are two types of nanopharmaceuticals: (1) those where the therapeutic molecules are themselves the drug (i.e.,the therapeutic compound itself also functions as its own carrier); and (2) those where the therapeutic molecules are directly coupled (functionalized, entrapped, or coated) to a nanoparticle carrier.
This report aims to provide a comprehensive presentation of the global market for Nanopharmaceutical Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanopharmaceutical Drugs. This report contains market size and forecasts of Nanopharmaceutical Drugs in global, including the following market information:
- Global Nanopharmaceutical Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
- Global Nanopharmaceutical Drugs Market Sales, 2018-2023, 2024-2029, (K MT)
Global top five Nanopharmaceutical Drugs companies in 2022 (%)
The global Nanopharmaceutical Drugs market was valued at US$ 31860 million in 2022 and is projected to reach US$ 54500 million by 2029, at a CAGR of 8.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
USA is the largest Nanopharmaceuticals market with about 59% market share. Europe is follower, accounting for about 33% market share.
The key players are Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy etc. Top 3 companies occupied about 34% market share.
We surveyed the Nanopharmaceutical Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Nanopharmaceutical Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K MT)
Global Nanopharmaceutical Drugs Market Segment Percentages, by Type, 2022 (%)
- Liposomes
- Polymer
- Nanocrystals
- Protein
- Others
Global Nanopharmaceutical Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K MT)
Global Nanopharmaceutical Drugs Market Segment Percentages, by Application, 2022 (%)
- Oncology
- Neurology
- Immunology
- Anti-Infective
- Cardiovascular
- Others
Global Nanopharmaceutical Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K MT)
Global Nanopharmaceutical Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Nanopharmaceutical Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Nanopharmaceutical Drugs revenues share in global market, 2022 (%)
- Key companies Nanopharmaceutical Drugs sales in global market, 2018-2023 (Estimated), (K MT)
- Key companies Nanopharmaceutical Drugs sales share in global market, 2022 (%)
key players include:
- Pfizer
- Merck
- AstraZeneca
- Gilead Sciences
- Abbvie
- Amgen
- Roche
- Novartis
- Sanofi
- Outline of Major Chapters:
- Chapter 1: Introduces the definition of Nanopharmaceutical Drugs, market overview.
- Chapter 2: Global Nanopharmaceutical Drugs market size in revenue and volume.
- Chapter 3: Detailed analysis of Nanopharmaceutical Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Nanopharmaceutical Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: Global Nanopharmaceutical Drugs capacity by region & country.
- Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
- Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
- Chapter 11: The main points and conclusions of the report.
